Stoke Therapeutics’ (STOK) Buy Rating Reaffirmed at Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating restated by Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $22.00 target price on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 145.54% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the company. Chardan Capital assumed coverage on Stoke Therapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $24.00 price target on the stock. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Finally, Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective for the company. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Trading Down 3.8 %

STOK opened at $8.96 on Wednesday. The company has a 50 day moving average of $11.98 and a 200 day moving average of $13.08. Stoke Therapeutics has a 12 month low of $4.09 and a 12 month high of $17.58. The company has a market cap of $474.58 million, a PE ratio of -4.27 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. Research analysts forecast that Stoke Therapeutics will post -2.03 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 13,945 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $178,217.10. Following the completion of the sale, the insider now owns 47,332 shares of the company’s stock, valued at $604,902.96. This represents a 22.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Jonathan Allan sold 9,696 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the transaction, the general counsel now owns 35,142 shares in the company, valued at $449,114.76. The trade was a 21.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in shares of Stoke Therapeutics by 28.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 115,892 shares of the company’s stock valued at $1,566,000 after acquiring an additional 25,988 shares during the last quarter. Rhumbline Advisers increased its stake in Stoke Therapeutics by 14.3% in the 2nd quarter. Rhumbline Advisers now owns 47,860 shares of the company’s stock worth $647,000 after purchasing an additional 5,990 shares during the period. Los Angeles Capital Management LLC lifted its position in Stoke Therapeutics by 7.2% in the second quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock valued at $902,000 after purchasing an additional 4,508 shares during the last quarter. Quest Partners LLC purchased a new stake in shares of Stoke Therapeutics during the second quarter valued at approximately $29,000. Finally, American Century Companies Inc. grew its holdings in shares of Stoke Therapeutics by 99.4% in the second quarter. American Century Companies Inc. now owns 59,149 shares of the company’s stock worth $799,000 after purchasing an additional 29,489 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.